Drugs / Cytotect®CP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05370976 | Sep 2022 → Aug 2023 | cytomegalovirus infection | University Hospital, Lille | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CytotectCP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05370976 ↗ |
| Modality | Protein / enzyme biologic | “Hyperimmune Anti-CMV IVIg” NCT05370976 ↗ |
| Route | Intravenous | “Hyperimmune Anti-CMV IVIg” NCT05370976 ↗ |